EGFR and lung carcinoma: We have also described an EV surface functionalization approach that facilitates EGFR‐targeted delivery of paclitaxel‐loaded RBCEVs to EGFR‐positive lung cancer cells and increases treatment efficacy in vivo (Pham et al., 2021).